Innnovation leading to impact
A startup company with a vision and ambitions to develop the Wenemea solution.
With Wenemea solution chemotherapy induced peripheral neuropathy* (CIPN) can be monitored easier, leading to earlier action, including improved medication and improved quality of life for breast cancer patients.
[a result of damage to the nerves located outside of the brain and spinal cord (peripheral nerves)]*
The disorder, CIPN, is accompanied by multiple symptoms with long-term functional impairment affecting quality of life e.g., sensory and functional deteriorations as well as severe pain.
Tingling and burning pain in hands and feet. These are side effects which affect more than half of the breast cancer patients who are treated with certain types of chemotherapy.
There is no treatment for nerve pain.
The basic idea of Wenemea was a spin out of Martin Nors Skov PhD at Aarhus University. The project has so far been financially supported by BioInnovation Institute Foundation (BII) Proof-of-Concept grant. Aarhus University and The International Diabetic Neuropathy Consortium and the Innofounder by Innovationsfonden.